Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism

Investigational New Drugs

Volumn 21, Issue 4, 2003, Pages 435-443

  Font, Albert ^a   Sánchez, José Miguel ^a   Tarón, Miquel ^a   Martinez Balibrea, Eva ^a   Sánchez, José Javier ^b   Manzano, José Luis ^a   Margelí, Mireia ^a   Richardet, Martin ^a   Barnadas, Agustí ^a   Abad, Albert ^a   Rosell, Rafael ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF MADRID   (Spain)

Author keywords

CPT 11; Pharmacogenetic screening; SN 38

Indexed keywords

CREATININE; DOCETAXEL; GLUCURONOSYLTRANSFERASE; IRINOTECAN; ISOENZYME;

ADULT; AGED; ALLELE; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 9144265660     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026251202137     Document Type: Article

References (28)

1. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 5: 1087-1100, 1998
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, for the Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002
3. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001
4. Huisman C, Smit EF, Giaccone G, Postmus PE: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18: 3722-3730, 2000
5. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkess R, Coughlin S, Kim Y, Berile J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000
6. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kaiman L, Miler V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L, and the TAX 320 Non-Small-Cell Lung Cancer Study Group: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18: 2354-2362, 2000
7. Koh Y, Nishio K: Mechanisms of action of cancer chemotherapeutic agents: topoisomerase inhibitors. In: Alison MR (ed) The Cancer Handbook. Nature Publishing Group, London, 2002 pp 1313-1322
8. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucoronosyltransferase isoform 1A1 in the glucoronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854, 1998
9. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, Ratain MJ. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65: 576-582, 1999
10. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. The Pharmacogenomics J 2: 43-47, 2002
11. Tarón M, Plasencia C, Abad A, Martin C, Guillot M: Cytotoxic effects of topotecan combined with various active G2/ M-phase anticancer drugs in human tumor-derived cell lines. Inv New Drugs 18: 139-147, 2000
12. Satouchi M, Takada Y, Takeda K, Yamamoto N, Negoro S, Nakagawa K, Matsui K, Kawahara M, Fukuoka M, Ariyoshi H: Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC): a West Japan Thoracic Oncology Group (WJTOG) study. Proc Am Soc Clin Oncol 20: 329a, 2001 (Abstract 1312)
13. Font A, Sánchez JM, Rosell R, Tarón M, Martínez E, Guillot M, Manzano JL, Margelí M, Barnadas A, Abad A: Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung Cancer 37: 213-218, 2002
14. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK, Raber M: Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 13: 645-651, 1995
15. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C: Activity of docetaxel in platinum-treated non-small-cell lung cancer. Results of a phase II multicenter trial. J Clin Oncol 18: 131-135, 2000
16. Crino L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Della Giulia M, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M, Tonato M: Gemcitabine as secondline treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 17: 2081-2085, 1999
17. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18: 1212-1219, 2000
18. Stemmler HJ, Gutschow K, Sommer H, Malekmohammadi M, Kentenich CH, Forstpointner R, Geuenich S, Bischoff J, Hiddemann W, Heinemann V: Weekly docetaxel (taxotere) in patients with metastatic breast cancer. Ann Oncol 12: 1393-1398, 2001
19. 2 weekly in patients with pretreated non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 310a, 2002 (Abstract 1238)
20. Couteau C, Risse ML, Ducreux M, Lefresne-Soulas F, Riva A, Lebecq A, Ruffié P, Rougier P, Lokiec F, Bruno R, Armand JP: Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J Clin Oncol 18: 3545-3552, 2000
21. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C: Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 18: 1116-1123, 2000
22. Sande JR, Verdirame J, Hillman S, Geyer S, Drevyanko T, Tazelaar H, Jett J, Adjei AA: A phase II study of irinotecan and docetaxel in patients with recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 324a, 2002 (Abstract 1295)
23. Rougier P, Cutsem EV, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus flurouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998
24. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343; 905-914, 2000
25. Innocenti F, Iyer L, Ratain MJ: Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Disposition 29: 596-600, 2001
26. Kehrer DFS, Sparreboom A, Verweij J, Bruijin P, Nierop CA, Van de Schraaf J, Ruijgrok EJ, De Jonge MJA: Modulation of irnotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7: 1136-1141, 2001
27. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000
28. Mathijssen RHJ, Van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194, 2001